Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

Pi moderators publicly rejected the "Global Consensus Value" myth as harmful misinformation, with the launch preparation of Map of Pi 2.0. Summary is AI generated, newsroom reviewed. Pi moderators ...

Pi Network whale accumulation boosts PI coin despite Bitcoin and Ethereum losses. Map of Pi 2.0 to enable real-world transactions with 140,000+ merchants. Moderators debunk GCV, emphasising utility ...

Having launched the Raspberry Pi Zero W in 2017 as an upgrade to 2015’s Raspberry Pi Zero, Raspberry Pi Foundation has now unveiled its latest offering, the Raspberry Pi Zero 2 W. In this article, we ...

These are direct-prediction models trained from scratch on small, heavily augmented datasets—not few-shot prompting. ARC remains the canonical target; broader leaderboard context and rules (e.g., ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...

RXRX's CDK7 inhibitor REC-617 has demonstrated activity but additional data from the ELUCIDATE trial in various solid tumors isn't expected until H2'25. Near-term catalysts include phase 2 TUPELO ...

Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...